Lutris Pharma to Present Updated Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the EADV Congress
TEL AVIV, Israel, Sept. 16, 2026 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving the quality of life and drug adherence for patients treated with anti-cancer therapies by mitigating dermatological toxicities, today announced the presentation...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Monster Energy's Joshua Van Defeats Alexandre Pantoja to Retain UFC Flyweight Championship Title at UFC 331 in Los Angeles
- SparkLabs and Mirae Asset Launch a Venture Capital Fund for Central Asian Startups
- Huawei Digital Power präsentiert auf der IDEE 2026 Lösungen für verschiedene Anwendungsszenarien mit den Schwerpunkten Netzbildung und KI
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →